Projects funded by the NCN

Next-Generation Exosome Therapy: Engineering NK Cell-Derived Vesicles for Targeted Cancer Treatment

Call: SONATINA 9 , Panel: NZ6

Principal investigator: dr Daria Nawrocka

Instytut Immunologii i Terapii Doświadczalnej im. Ludwika Hirszfelda Polskiej Akademii Nauk

Selective autophagy-mediated protein degradation as a potential therapeutic strategy for the treatment of inflammatory c...

Call: OPUS 28 , Panel: NZ7

Principal investigator: dr hab. Monika Emilia Marcinkowska

Uniwersytet Jagielloński

Identification of circulating biomarkers for monitoring anti-CD19 CAR-T cell treatment response in patients with aggress...

Call: PRELUDIUM 23 , Panel: NZ5

Principal investigator: Monika Szelest

Uniwersytet Medyczny w Lublinie

Curdlan-based biomaterial as a nanostructure carrier for controlled and targeted drug delivery in the treatment of deep ...

Call: PRELUDIUM 22 , Panel: NZ7

Principal investigator: dr Aleksandra Nurzyńska

Uniwersytet Medyczny w Lublinie

Cuproptosis, a novel pathway of regulated cell death as a therapeutic target in treatment-naïve and targeted therapy-res...

Call: OPUS 25 , Panel: NZ5

Principal investigator: dr hab. Mariusz Łukasz Hartman

Uniwersytet Medyczny w Łodzi, Wydział Lekarski

Targeting of metabolic and transcriptomic cross-talk between leukemic cells and macrophages as a therapeutic strategy in...

Call: OPUS 22 , Panel: NZ5

Principal investigator: dr Baran Natalia

Instytut Hematologii i Transfuzjologii

New strategies in the treatment of non-small cell lung cancer based on silk nanocarriers targeting tumor vascularization

Call: SONATA 17 , Panel: NZ7

Principal investigator: dr Anna Katarzyna Florczak-Substyk

Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

New insights into multifaceted targeted therapy for treatment of glioblastoma multiforme.

Call: OPUS 18 , Panel: NZ5

Principal investigator: dr Katarzyna Anna Malarz

UNIWERSYTET ŚLĄSKI, Wydział Nauk Ścisłych i Technicznych

The role of MCPIP1 as a potential tumor suppressor during development and treatment of clear cell renal cell carcinoma

Call: PRELUDIUM 13 , Panel: NZ5

Principal investigator: dr Paulina Marona

Uniwersytet Jagielloński, Wydział Biochemii, Biofizyki i Biotechnologii

Hypoxia compensation into physioxia to normalize/regenerate ischaemc tissues. Effects of microRNA regulation for targete...

Call: OPUS 12 , Panel: NZ1

Principal investigator: prof. Claudine Marie-Thérèse Kieda

Wojskowy Instytut Medyczny

Long non-coding RNAs (lncRNA) as treatment efficacy markers in patients with advanced melanoma harboring BRAF mutation.

Call: OPUS 11 , Panel: NZ7

Principal investigator: dr hab. Jacek Mackiewicz

Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Wydział Nauk o Zdrowiu

Targeted inhibition of STATs and IRFs as a novel treatment strategy in cardiovascular disease

Call: OPUS 9 , Panel: NZ2

Principal investigator: prof. Johannes Antonius Bluijssen (Bluyssen)

Uniwersytet im. Adama Mickiewicza w Poznaniu, Wydział Biologii